chore: daily update 2026-08-09

2026-08-09 02:33:45 +08:00
parent 06f60e166b
commit 3267338ba9
28 changed files with 1020 additions and 370 deletions
@@ -1,7 +1,8 @@
 ---
 type: "Reference"
 title: "Commitments"
-openwiki_generated: true
+description: "Active work tasks, follow-ups, approvals, and scheduled items extracted from sources (web-search, git-repo, literature flywheel-sync, etc.). Personal errands live in /personal-logistics.md instead."
+tags: [commitments, work, follow-ups, distributors-2026-08-07-refresh, dong-huiqun-ji-nan-chengquan-link]
 ---

 # Commitments
@@ -73,6 +74,41 @@ Concrete work tasks, follow-ups, approvals, and scheduled items extracted from G
 - Status: open
 - Notes: Personal-infra work item (workflow-tooling priority LOW), not vendor-anchored — logged here because it is source-anchored to Robin's actual vault work per the brief's commitments.md rule ("only real Robin commitments"). Plan: mATX + i5-12400 + DDR4-2666 32G + 板载 Realtek 1Gb + Intel PRO/1000 GT (¥2,985.82, 10/11 parts on hand). Two 网卡 VLAN: 192.168.31.100 → 主力机 Win 11 SSH, 10.10.10.254 → 主力 NAS RAGFlow. Post-assembly steps: Ubuntu Server 22.04 LTS install, partition `/` (GM7 512G) + `/data` (mSATA 512G), Docker, dual-NIC 静态 IP, 主力机 SSH key 免密, NAS RAGFlow API 接入, 安装 Hermes Agent, 24h 跑功耗 soak test. The host has no vendor-product overlap; not promoted to `/themes.md` row because that index is reserved for recurring workflow signals.

+### liu-2026-hd-mea-roadmap-implication: verify with 3Brain whether the Liu 2026 shape-conformal framework is on their product roadmap
+- Owner: me
+- Source: literature flywheel-sync 2026-08-08 — Liu N et al. (2026) Nature Biomedical Engineering, DOI 10.1038/s41551-026-01620-y, Wiki.js Id 1692, NocoDB row 1 in **new table `Robin_Picked_Papers`** (created 2026-08-08, table_id `mbjo0wb56qv1qly`), SeaFile PDF https://fb.biokingdom.top/f/6da50240729e41bdb369/?dl=1. Deep-read synthesis at [`/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md`](/sources/literature-liu-2026-nbme-shape-conformal-organoid-deepread.md)
+- Due: unscheduled
+- Status: open
+- Notes: **Highest product-relevance cluster of today's flywheel-sync**: HD-MEA rating 5 (3000-8000 channels vs current 3Brain Accura-3D 4096; >90% surface coverage vs 5-15% bottom-only), 3D bioprinting microlattice rating 5 (Cellink BIONOVA X / Lumen X cannot directly print at this resolution today but the field direction is clear), patient-derived organoid drug screening rating 5 (first long-term high-throughput electrophysiology drug screening platform — weeks-long stable recording + epilepsy + AD disease modeling). Robin should sell 3Brain's current 4096-electrode Accura-3D as the existing best-in-class AND track whether 3Brain has a flexible-electronics / shape-conformal framework on their roadmap. Companion question on `/open-questions.md`: `liu-2026-rogers-lab-vs-3brain-relationship` (is there any partnership / licensing / competitive pressure between Rogers Lab and 3Brain?). Companion commitment to verify with Cellink: `liu-2026-cellink-microlattice-positioning` (whether BIONOVA X or Lumen X can fabricate flexible-electronics-compatible microlattices).
+
+### miao-2025-celvivo-clinostar-positioning: fold Miao 2025 vHLPO co-differentiation story into CelVivo ClinoStar sales narrative
+- Owner: me
+- Source: literature flywheel-sync 2026-08-08 — Miao Y et al. (2025) Cell v2, DOI 10.1016/j.cell.2025.05.041, PMID 40592324, Wiki.js Id 1681, NocoDB row 93, SeaFile PDF https://fb.biokingdom.top/f/24704d54a95941449e2e/?dl=1. Deep-read synthesis at [`/sources/literature-miao-2025-cell-vascularization-v2-deepread.md`](/sources/literature-miao-2025-cell-vascularization-v2-deepread.md)
+- Due: unscheduled
+- Status: open
+- Notes: **Strongest CelVivo ClinoStar product relevance rating (5) in any of the 3 new flywheel-sync papers** — the vHLPO single 3D EB co-induction (mesoderm+endoderm) protocol depends on 3D EB self-organization in low-shear rotating culture, which is exactly what ClinoStar provides. vHLPO 7% ECs vs traditional HLPO 0% is a clinically-meaningful differentiator that no competing 2D / static culture can match. Sales ammunition: "your lung organoid model is missing 100% of vasculature — ClinoStar co-differentiation gives you 7% ECs vs 0%". Cross-vendor co-marketing: CelVivo ClinoStar (culture) + Cellink BIO X (decellularized lung scaffold) + 3Brain HD-MEA (functional readout on the neural mesenchyme). Robin should fold this into the CelVivo industrial-customers program (existing `CelVivo_中国工业客户开发研究报告` v1 + v2 in vault) and pitch to pediatric-hospital pharma R&D accounts (FOXF1 ACDMPV rare disease).
+
+### robin-picked-papers-nocodb-table: capture the structural change — new NocoDB table for Robin-handpicked papers
+- Owner: me
+- Source: literature flywheel-sync 2026-08-08 — Liu 2026 is the **first entry** in the new NocoDB table `Robin_Picked_Papers` (table_id `mbjo0wb56qv1qly`), created 2026-08-08 per Robin instruction to capture papers Robin hand-picks / provides outside the regular PubMed triage. The table is separate from the existing `Organoid_Literature` table.
+- Due: unscheduled
+- Status: open
+- Notes: The new table has 9 fields: Title, DOI, Journal, Year, Authors, Source, wiki_url, pdf_url, deep_read_summary. Future handpicked papers should land in this table rather than in `Organoid_Literature` (which is PubMed-triage-driven). Verify with Robin: (a) what is the workflow for capturing a handpicked paper — manual PDF drop to `/home/ldw/.hermes/cache/documents/` and then trigger the LDR pipeline; (b) should the LDR pipeline auto-route by signal (PubMed triage vs handpicked), or does Robin always provide the routing signal.
+
+### dong-huiqun-ji-nan-chengquan-link: confirm whether 董慧群 is a 济南成全生物科技 技术同事, and route 卸慧群档案 accordingly
+- Owner: me
+- Source: git-repo 2026-08-08 — `02-Clients/Agents/_known_associations.md` (commit `4b237a82`, Hermes Agent 2026-08-07 hook 4) maps 济南成全生物科技有限公司 (曹沛起) as the **only CelVivo ClinoStar-listed agent** in the 259-dealer China map (华北 + 山东 跨区重复登记). `02-Clients/Agents/董慧群.md` (2026-07-28 commit `21491578`) lists 董慧群 as CelVivo 产品技术同事 with `agency: 待补`.
+- Due: unscheduled
+- Status: open
+- Notes: The 2026-08-07 hook 4 partial-resolution gave a likely candidate (济南成全生物科技 曹沛起 company) but the precise link to 董慧群 (and whether she is 济南成全的技术同事, or another dealer) is still unverified. Action: Robin to verify with 董慧群 directly via WeChat / 微信 (current open-question [`/open-questions.md`](/open-questions.md) `agent-dong-huiqun-celvivo`). Once confirmed: update `02-Clients/Agents/董慧群.md` frontmatter `agency` field, and update [`/sources/agents.md`](/sources/agents.md) "代理商品牌" column from "待补" to "济南成全生物科技 (曹沛起)". Until this is done, 董慧群's role in the 济南成全 book of business is unconfirmed.
+
+### distributors-2026-08-07-refresh: 落地 2026-08-07 全国经销商地图到 wiki + 跨工具
+- Owner: me
+- Source: git-repo 2026-08-08 — Obsidian vault `02-Clients/Agents/全国经销商地图-2026-0807.md` + 7 区域分文件 (8-07 baseline, 259 dealers across 7 regions, net change -2 from 2026-07-24 baseline). Vault raw survives 2026-08-08 fetch as untracked files (commit `4b237a82` Lin Yongli "4 个经销商管理 Hook 升级").
+- Due: unscheduled
+- Status: open
+- Notes: 8-07 baseline differs from 7-24 baseline in: (a) total 261 → 259 (华北 74 → 72); (b) 济南成全生物科技有限公司 (曹沛起) cross-region registration (华北 + 山东); (c) new `_known_associations.md` index maps CelVivo → 济南成全 / FemtoBiomed → 9X Bio → TriArm / 3Brain + Cellink → 0. Cross-reference: [`/sources/distributors-china-2026.md`](/sources/distributors-china-2026.md) has been updated to the 8-07 baseline + new associations table; [`/sources/agents.md`](/sources/agents.md) still needs the 董慧群 → 济南成全 link; [`/commitments.md`](/commitments.md) has follow-up for 成都百乐 vs 成都立德赛 decision (open-question `chengdu-baile-vs-lidesai-for-ou-xianhong`). End-customer coverage for 3Brain / Cellink / FemtoBiomed still 0 in the 259 baseline — see open-question `distributors-3brain-cellink-zero-coverage`.
+
 <!--
 Structure for new entries: